MoonLake Immunotherapeutics Class A Ordinary Shares
MLTX
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
Last trade$11.09
Day change-$0.64 (-5.46%)
Day range$11.01 – $11.81
Volume614,962
Market cap$998M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$998.3M
Price / earnings
—
Price / book
2.62×
Price / sales
—
EV / sales
—
EV / EBITDA
-2.63×
Profitability
Earnings per share
-$3.19
Return on assets
-50.13%
Return on equity
-71.03%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.26×
Current ratio
9.13×
Quick ratio
9.13×
Cash ratio
6.5×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$244.04M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MLTX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$10.98M
$11.44M
$15.51M
$9.21M
$10.8M
$10.94M
$11.03M
$9.22M
Research and development
$68.87M
$50.22M
$54.52M
$56.01M
$60.64M
$49.76M
$36.46M
$40.36M
Total operating expenses
$79.85M
$61.66M
$70.02M
$65.22M
$71.43M
$60.7M
$47.49M
$49.58M
Operating income
-$79.85M
-$61.66M
-$70.02M
-$65.22M
-$71.43M
-$60.7M
-$47.49M
-$49.58M
Interest expense
-$2.66M
-$2.63M
-$2.27M
-$1.99M
-$3.2M
-$2.04M
-$18K
$0
Income before taxes
-$78.91M
-$61.72M
-$69.09M
-$62.77M
-$70.58M
-$55.96M
-$40.41M
-$46.35M
Income taxes
$631K
$90K
$622K
$248K
$115K
$95K
$153K
$41K
Net income
-$79.55M
-$61.81M
-$69.71M
-$63.02M
-$70.69M
-$56.05M
-$40.56M
-$46.4M
Net income attributable to common shareholders
-$79.55M
-$61.81M
-$69.71M
-$60.02M
-$69.73M
-$55.22M
-$39.94M
-$44.09M
EBITDA
-$78.95M
-$60.76M
-$69.18M
-$64.47M
-$70.69M
-$59.96M
-$47.11M
-$49.22M
Basic earnings per share
-$0.93
-$0.84
-$0.98
-$0.88
-$1.10
-$0.87
-$0.63
-$0.70
Diluted earnings per share
-$0.93
-$0.84
-$0.98
-$0.88
-$1.10
-$0.87
-$0.63
-$0.70
Recent news
Company coverage with links to the original publishers.
The psoriatic arthritis market is expected to expand significantly through 2036 driven by emerging late-stage therapies from major pharmaceutical companies. Key drugs in development include tildrakizumab (Sun Pharma), sonelokimab (MoonLake), icotrokinra (Johnson & Johnson), zasocitinib (Takeda), izokibep (Affibody Medical), and vunakizumab (Suzhou Suncadia). These novel biologic and oral small-molecule therapies aim to address unmet needs among patients with inadequate responses to existing treatments.
MoonLake Immunotherapeutics CFO Matthias Bodenstedt sold 39,120 shares worth approximately $862,000 on June 22 through a pre-planned 10b5-1 trading plan. The sale represented 3.4% of his direct holdings, leaving him with over 1.1 million shares. While the transaction shouldn't concern investors due to its pre-planned nature, the clinical-stage biotech company remains highly volatile with no approved products or revenue.
MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotech company, announced the pricing of an underwritten public offering of 9 million Class A ordinary shares at $20.00 per share and 1 million pre-funded warrants, expected to raise approximately $200 million in gross proceeds. The company plans to use the net proceeds to fund research, development, and commercialization activities for sonelokimab, its investigational treatment for inflammatory diseases including hidradenitis suppurativa and psoriatic arthritis. The offering is expected to close on or about June 25, 2026.
MoonLake Immunotherapeutics CEO Jorge Santos da Silva sold 150,000 shares worth approximately $2.8 million on April 10-13, 2026, reducing his direct holdings by 4.9%. While the sale is not necessarily alarming given his substantial remaining stake of nearly 3 million shares, the company remains a high-risk investment. MoonLake's stock has fallen 47.47% over the past year following disappointing clinical trial results for its lead therapy Sonelokimab, though the FDA granted it fast-track designation. The pre-revenue biotech company burns approximately $65 million quarterly but has $394 million in cash reserves.
BVF Partners L.P., a biotech-focused hedge fund, sold 3.75 million shares of MoonLake Immunotherapeutics for approximately $63 million on April 2, 2026, reducing its direct stake by 78.3%. The sale appears to be portfolio rebalancing rather than a full exit, as BVF retains 15.9 million shares. MoonLake, a clinical-stage immunotherapy company developing sonelokimab for inflammatory diseases, has experienced a 53.35% stock decline over the past year despite recent positive clinical trial results.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.